Month: September 2026

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit the Smith+Nephew booth during ICSES to learn more about the following technologies:

TENDON SEAM Rotator Cuff Repair System
Recently acquired by Smith+Nephew, the TENDON SEAM System is a unique rotator cuff repair solution that offers superior load sharing designed to maximize repair strength throughout the healing period.^1-4,*,** The construct features multiple tightly spaced 2x10mm anchors connected by a continuous stitch designed to distribute forces across the repaired tendon with a seam of fixation perpendicular to the direction of load. Biomechanical testing demonstrates a 2X increase in repair strength and 10X decrease in gap formation compared with traditional techniques, ^1-4,* with encouraging early clinical outcomes.⁵ View the TENDON SEAM Rotator Cuff Repair System webpage here.

REGENETEN^◊ Bioinductive Implant
With more than 250,000 procedures⁶ completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact for rotator cuff repair, demonstrating reduced risk of retear^*** and benefits for patient recovery.^7-9,± The bioinductive implant, with highly purified, highly porous, highly oriented collagen fibers, supports the body’s natural healing response to facilitate the formation of new tissue.^10-14 A study published earlier this year concluded that early recovery time was halved following isolated use of the REGENETEN Implant for partial thickness rotator cuff tears when compared with a traditional suture anchor repair.^15,±,‡ Patients also enjoyed a better shoulder-related quality of life at 6 weeks and 3 months.^15,±,‡ Learn more about the REGENETEN Bioinductive Implant in partial-thickness tears, including the recent 4-star recommendation from AAOS for bioinductive implants, by visiting the webpage here.

Q-FIX^◊ KNOTLESS 2.8 All-Suture Anchor – Launching at ICSES!
The Q-FIX KNOTLESS 2.8 All-Suture Anchor is designed for the shoulder surgeon that wants best-in-class reliability,^16,† but in a knotless construct which allows fine-tuned tensioning of soft tissue. The Q-FIX KNOTLESS 2.8 Anchor has the versatility to meet the needs of various surgical procedures, tissue/bone quality, or surgeon preference, in different anatomies and surgical procedures.​ To learn more about the Q-FIX KNOTLESS family of all-suture anchors, please see the product brochure here.

Differentiated shoulder arthroplasty technology for personalized care 
CORIOGRAPH^◊ Pre-Op Planning and Modeling Services and CORI^◊ SHOULDER Handheld Robotics Arthroplasty with the AETOS^◊ Shoulder System offer a complete robotic procedure supporting handheld robotic execution of the humerus and glenoid, across both anatomic and reverse procedures. 
 
Skill amplified. The freedom of handheld robotics. 
The best technology works naturally with surgical skill. The CORI XT Handheld Robotics Platform seamlessly integrates with current surgical workflows and was designed with a footprint tailored to the unique needs of hospitals and ambulatory surgical suite settings.¹⁷ It has a leaner platform configuration which moves easily between rooms.^18,¥  
 
For more information about CORIOGRAPH Pre-Op Planning Services and CORI SHOULDER Handheld Robotics Arthroplasty, please visit the webpage here. If you will be attending ICSES, be sure to join our CORI SHOULDER Handheld Robotics Arthroplasty evening event on Sept 22. Click here to register: https://lnkd.in/eM5CJ3QW. Spaces are limited.

– ends –

Media Enquiries
Dave Snyder          +1 (978) 749-1440 
Smith+Nephew      david.snyder@smith-nephew.com

*In biomechanical testing in human cadavers

**compared to traditional techniques

***Compared to standard repairs alone in medium or large full-thickness tears. 12 month re-tear rate – 8.3% vs 25.8% Relative risk=0.32 [95% Confidence Interval 0.13-0.83]; p=0.0106.

±Compared to takedown and (suture anchor) repair.

‡Rehabilitation protocols differed between treatment groups: isolated REGENETEN Implant use employed a faster post-op rehab protocol vs traditional repair.

†As compared to the competitive device in cyclic benchtop testing

¥Compared to Mako™ and ROSA®

References

1. Integrity Orthopaedics Data on File. Testing Report: DN-00664.
2. Park MC, Tibone JE, ElAttrache NS, Ahmad CS, Jun BJ, Lee TQ. Part II: Biomechanical assessment for a footprint-restoring transosseous-equivalent rotator cuff repair technique compared with a double-row repair technique. J Shoulder Elbow Surg. 2007;16(4):469-476.
3. Busfield BT, Glousman RE, McGarry MH, Tibone JE, Lee TQ. A Biomechanical Comparison of 2 Technical Variations of Double-Row Rotator Cuff Fixation The Importance of Medial Row Knots. The American Journal of Sports Medicine. 2008;36(5).
4. Abtahi AM, Granger EK, Tashjian RZ. Factors affecting healing after arthroscopic rotator cuff repair. World J Orthop. 2015 Mar 18;6(2):211-20.
5. Dr Frix JT. Novel Tendon-to-Bone Seam Technique for Rotator Cuff Repair. Presentation at Orthopaedic Summit (OSET); September 19-21st 2025; Las Vegas, NV.
6. Smith+Nephew. Internal Data.
7. Bushnell BD, Bishai SK, Krupp RJ, et al. Treatment of Partial-Thickness Rotator Cuff Tears With a Resorbable Bioinductive Bovine Collagen Implant: 1-Year Results From a Prospective Multicenter Registry. Orthop J Sports Med. 2021;9(8):23259671211027850. Published 2021 Aug 13. doi:10.1177/23259671211027850
8. Camacho Chacón JA, Roda Rojo V, Martin Martinez A, et al. An isolated bioinductive repair vs sutured repair for full-thickness rotator cuff tears: 2-year results of a double blinded, randomized controlled trial. J Shoulder Elbow Surg. 2024;33(9):1894-1904. doi:10.1016/j.jse.2024.03.043Bokor DJ, et al. Muscles, Ligaments Tendons J 2016;6(1):16-25.
9. Ruiz Ibán MÁ, García Navlet M, Moros Marco S, et al. Augmentation of a Transosseous-Equivalent Repair in Posterosuperior Nonacute Rotator Cuff Tears With a Bioinductive Collagen Implant Decreases the Retear Rate at 1 Year: A Randomized Controlled Trial. Arthroscopy. 2024;40(6):1760-1773. doi:10.1016/j.arthro.2023.12.014
10. Smith+Nephew 2020 REGENETEN Collagen Implant Physical Characteristics. Internal Report Internal Report. 15009769.
11. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J 2016;6(1):16-25.
12. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251.
13. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235.
14. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283.
15. Wang A, et al. Orthop J Sports Med. 2026;14(3):23259671261418675.
16. Smith+Nephew. Internal Report. 10144423 Rev B
17. Smith+Nephew 2020. Internal report. ER0488 Rev.B
18. Smith+Nephew 2020. Comparison of operating room footprint for robotic-assisted knee arthroplasty systems. Internal Report. EO.REC.PCS015.002.v1.

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

WYOMISSING, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) announced today that the Company will release its 2026 third quarter financial results after the market close on Thursday, October 29, 2026. The Company will host a conference call at 10:00 a.m. ET on Friday, October 30, 2026.

During the conference call, Peter M. Carlino, Chairman and Chief Executive Officer, and senior management, will review the quarter’s results and performance, discuss recent events and conduct a question-and-answer period.

Webcast:
The conference call will be available in the Investor Relations section of the Company’s website at www.glpropinc.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software. A replay of the call will also be available for 90 days on the Company’s website.

To Participate in the Telephone Conference Call:
Dial in at least five minutes prior to start time.
Domestic: 1-877/407-0784
International: 1-201/689-8560

Conference Call Playback:
Domestic: 1-844/512-2921
International: 1-412/317-6671
Passcode: 13762758
The playback can be accessed through Friday, November 6, 2026.

About Gaming and Leisure Properties
GLPI is engaged in the business of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements, pursuant to which the tenant is responsible for all facility maintenance, insurance required in connection with the leased properties and the business conducted on the leased properties, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties.

Contact:
Gaming and Leisure Properties, Inc.                
Carlo Santarelli, SVP – Corporate Strategy & Investor Relations
610-378-8232
csantarelli@glpropinc.com

Investor Relations
Joseph Jaffoni, Christin Armacost at JCIR
212-835-8500
glpi@jcir.com

21 September 2026

LSE Code: 3UKS

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY
(a public company incorporated with limited liability in Ireland)
WISDOMTREE FTSE 100 3X DAILY SHORT SECURITIESISIN:IE00B7VB3908
RESULTS OF MEETING OF THE ETP SECURITYHOLDERS

WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”) wishes to announce that the Extraordinary Resolution regarding the reduction in the principal amount of the WisdomTree FTSE 100 3x Daily Short Securities (the “Affected Securities”) from GBx 20 to GBx 2, as set out in a notice to holders of the Affected Securities dated 27 August 2026, was passed at an adjourned meeting of the holders of the Affected Securities held at 11am on 21 September 2026.

As a result, the Deed of Amendment has been duly executed by the Issuer, the Manager and the Trustee to put the proposed amendments to the Trust Deed into effect from 21 September 2026.

Press Release

74Software: Disclosure of transactions in own shares

Paris, September 21, 2026 – In accordance with the authorization given by the Combined General Meeting of May 19, 2026, for the implementation of a share buyback program, 74Software (LEI: 96950022O6SP7FQONJ77) declares below the purchases of its own shares (FR0011040500) from September 14 to 18, 2026:

Details of transactions, in accordance with Article 5(2)(c) of European Regulation No 596/2014 and its delegated regulation (EU) 2016/1056, are available on page 2 and following.

Disclaimer

This document is a translation into English of an original French press release. It is not a binding document. In the event of a conflict in interpretation, reference should be made to the French version, which is the authentic text.

About 74Software

74Software is an enterprise software group founded through the combination of Axway and SBS – independently operated leaders with unique experience and capabilities to deliver mission-critical software for a data driven world. A pioneer in enterprise integration solutions for 25 years, Axway supports major brands and government agencies around the globe with its core line of MFT, B2B, API, and Financial Accounting Hub products. SBS empowers banks and financial institutions to reimagine tomorrow’s digital experiences with a composable cloud-based architecture that enables deposits, lending, compliance, payments, consumer, and asset finance services and operations to be deployed worldwide. 74Software serves more than 12,000 companies, including over 1,500 financial service customers. To learn more, visit 74Software.com

Contacts – Investor Relations:

Arthur Carli – +33 (0)1 47 17 24 65 – acarli@74software.com
Chloé Chouard – +33 (0)1 47 17 21 78– cchouard@74software.com

Detailed disclosure of trading in own shares from September 14 to 18, 2026

Attachment

• 21092026_74SW_PR_ShareBuyback_WeekSept14_EN